|
A blog from Alanna Shaikh, consisting entirely of out-of-context press releases.
Wednesday, June 19, 2013
Fwd: AJWS: CONGRESS MISSES HISTORIC OPPORTUNITY TO REFORM INTERNATIONAL FOOD AID
Fwd: Press Release: MCC Board Approves Georgia Compact
|
Monday, June 17, 2013
AJWS OPPOSES VISIT TO U.S. BY SUDANESE WAR CRIMINAL
|
Friday, June 14, 2013
CLAMP DOWN ON UK-LINKED TAX HAVENS KEY TO SUCCESS OF G8 - NEW REPORT
Embargo: 19:30 Friday June 14 2013
CLAMP DOWN ON UK-LINKED TAX HAVENS KEY TO SUCCESS OF G8
UK-linked tax havens are at the centre of a global financial system that encourages crime, corruption and aggressive tax avoidance in developing countries, reveals a new report from the Enough Food For Everyone IF campaign.
It highlights for the first time the huge scale of foreign investment routed through the UK's tax havens to poor countries – and the potential for abuse this causes.
The findings in Invested Interests: The UK's Overseas Territories' Hidden Role in Developing Countries underline the urgent need for the G8 to agree a tax deal that benefits poor countries.
Joseph Stead, IF spokesman and report author, said: "The UK as G8 chair has never been in a stronger position to end the grave injustices caused by tax havens – if the UK succeeds in putting its own house in order first.
"The Prime Minister must do everything he can to get UK havens agreed on a tax deal before he arrives in Northern Ireland, so he can push the G8 to end the tax scandal.
"The G8 can start to put an end to tax haven secrecy by agreeing to public registers of the beneficial ownership of all companies and trusts, and making sure developing countries benefit from any tax information deal."
The report reveals that the British Virgin Islands (BVI), Cayman Islands, Bermuda, Gibraltar, Anguilla and Turks and Caicos - all British Overseas Territories - together with the Crown Dependencies of the Isle of Man, Jersey and Guernsey are now the largest source of Foreign Direct Investment in developing countries.
The amount totalled US$556bn by 2011, the most recent year for which we have figures, and accounted for one in every ten US dollars of foreign direct investment made there. This figure is concerning because investment is often structured through such jurisdictions specifically to enable tax dodging in poor countries. Other abuses they facilitate include the laundering of crime money, and 'round tripping', in which money originating in the developing country where it is to be invested is sent offshore and then returned disguised as foreign funds to qualify for major tax breaks.
"All countries need foreign investment, particularly those fighting hunger and acute poverty," added Mr Stead. "But this needs to be genuine and bring real benefits, not money disguised for tax purposes to enrich the already wealthy, illicit money laundered to bestow legitimacy on the corrupt, or investment designed to shift profits out of developing countries.
"We need to clamp down on tax havens and launch a convention on tax transparency to stop the flow of billions of pounds out of developing countries – money that could be used to end hunger."
The report finds that the British Virgin Islands alone was the fourth largest investor to developing countries in 2011, with the amount involved US$388bn. Globally it provides investment more than 860 times the size of its own GDP.
That same year it was revealed that 45 newly incorporated companies in the BVI had acquired mining assets in the Democratic Republic of Congo at a loss, it was claimed, to the DRC's economy of US$ 5.5bn. The identity of those behind the companies remains secret.
Former UN secretary-general Kofi Annan warned recently that foreign investors making extensive use of tax havens 'facilitate tax evasion, and in some cases corruption.'
The IF campaign estimates that developing countries lose some US$160bn of tax revenues a year from multinationals shifting profits offshore before they can taxed.
Ends
For more information please contact: Andrew Hogg, Christian Aid Press Office. 0207 523 2058/07872 350534.
Notes to editors:
About Enough Food for Everyone IF:
- Enough Food for Everyone IF is a coalition of nearly 200 organisations which have joined together to campaign for action by the G8 on the issue of global hunger. The last time we worked together at this scale was for Make Poverty History. Now that the G8 group of world leaders are returning to the UK, we are demanding they take action on hunger. 2013 won't be the end of hunger, but it could be the beginning of the end. Join us at www.enoughfoodif.org or current Members of Enough Food for Everyone IF, visit www.bond.org.uk
- Joseph Stead is senior economic justice adviser at Christian Aid
Wednesday, June 5, 2013
Ten Years of Health Innovation in Africa: Progress Made But Sustained Engagement and Partnership Needed to Develop and Implement New, Adapted Treatments for Neglected Diseases
Ten Years of Health Innovation in Africa: Progress Made But Sustained Engagement and Partnership Needed
to Develop and Implement New, Adapted Treatments for Neglected Diseases
[Nairobi, Kenya - 5 June 2013] – Days after two landmark resolutions were adopted at the World Health Assembly – on neglected tropical diseases and on research and development (R&D), financing and coordination for the health needs of developing countries – over 400 scientists, representatives and ministers of health, ambassadors, national control programme representatives, African regulators, health workers, public health experts, and activists from 21 African countries and 10 others from around the world gather in Nairobi to take stock of health innovation for neglected diseases in Africa over the past decade. While progress has been made, and certain diseases are targeted for elimination, the need for strong leadership, coordination, and sustainable funding is as pressing as ever and is critical to achieving much-needed breakthroughs.
Participants in the event – 'A Decade of R&D for Neglected Diseases in Africa' – organized by the Drugs for Neglected Diseases initiative (DNDi) on the occasion of its 10-year anniversary, with its African founding partner, the Kenya Medical Research Institute (KEMRI), will look at progress to date, gaps needing to be filled, and current and future development of new, field-adapted, affordable treatments, diagnostics, and vaccines for neglected diseases and patients throughout Africa.
'Neglected patient medical needs specific to Africa are many, and as scientists and policymakers in Africa, we need to share research and resources across borders to save time and money to help those most in need,' said Dr Monique Wasunna, Director of DNDi Africa, and Assistant Director of Research at KEMRI. 'By harmonizing efforts across Africa, we can strengthen our ability to turn research into concrete solutions for the health needs of the most neglected.'
As an example, ten years ago, patients with sleeping sickness were treated with a century-old regimen of painful injections of an arsenic-based drug, which itself killed one in 20 patients. Today, an improved treatment option developed in 2009, a combination therapy of an oral drug with intravenous injections, has become the treatment of choice in all endemic countries. This improved treatment resulted from years of R&D efforts in sub-Saharan African countries afflicted by the disease. Today a new oral-only treatment is being tested by DNDi in remote areas of Africa, in trials that are of international standards.
'As the African scientific community, we need to strive to build the scientific excellence to take ownership of research for health,' said the Honorable Mr James Macharia, Cabinet Secretary for Health of Kenya. 'I believe Africa is ready to take a step in this field, to develop and implement integrated strategies for neglected diseases. But even with such integrated strategies, and the political will required to propel them, in addition to the resources required from them, we must not forget that the right tools for elimination are necessary to really see the elimination of many of these diseases,' he added.
Despite increased attention and investments over the past decade in research for neglected diseases, a recent analysis in The Lancet reported that only 1% of all health R&D investments in 2010 were for neglected diseases.[1] In a recent analysis, DNDi and MSF estimated that, while progress has been made over the past decade, still only 3.8% of newly approved drugs were for neglected diseases that accounted for 10.5% of the global disease burden.[2]
The current reflection on the progress in R&D for neglected diseases and patients in Africa comes at a time when WHO member states have also reported unprecedented progress in the control of many of these diseases. Elimination goals up to 2020 for several neglected tropical diseases such as sleeping sickness, visceral leishmaniasis, or lymphatic filariasis were set out early last year in the WHO NTD Roadmap,[3] and new health tools are needed to support this strategy.
DNDi and a number of other new partnership initiatives set up during the last decade are bringing together the public and private sectors, in collaboration with WHO, TDR, and others to develop such new health tools. While not the ultimate solution to R&D gaps, these new models contribute significantly to the fight against neglected diseases.
'DNDi has developed six new treatments for four neglected diseases in the past decade, but there are still other neglected diseases that continue to lack good treatment options. While this progress is a good start, the treatments delivered are far from optimal. We have not yet developed new modern drugs which could change the history of certain neglected diseases,' said Dr Bernard Pécoul, Executive Director of DNDi. 'To truly fight neglect, we must push for more innovation and access of new treatments together with adequate coordination with control programmes. Progress to date shows this can be done in and with countries in Africa.'
DNDi and partners in Africa have established two regional R&D disease networks: the Leishmaniasis East Africa Platform (LEAP), launched in 2003 in Khartoum, Sudan; and the Human African Trypanosomiasis (HAT) Platform, launched in 2005 in Kinshasa, Democratic Republic of the Congo. LEAP was instrumental in the development of the combination drug SSG&PM (sodium stibogluconate and paromomycin) for the treatment of visceral leishmaniasis (kala azar) in East Africa, while the HAT Platform played a major role in the development of NECT (nifurtimox-eflornithine combination therapy) for the treatment of late-stage sleeping sickness.
'Around the world we are moving ahead in leaps and bounds, as ten years ago, good clinical practice was not the norm. Africa has moved very quickly in in this field and in the regulatory area and in ethics review. We need very strong clinical and regulatory practice to do good R&D,' said Dr Charles Mgone, Executive Director of the European & Developing Countries Clinical Trials Partnership (EDCTP). 'But we have not yet been able to support capacity building from within, and we must be able to. Working together is the key,' he added.
Press contacts
Samantha Bolton (Nairobi): sbolton@dndi.org +254 728 846 923
Renee Olende (Nairobi): rolende@dndi.org +254 705 639 909
Violaine Dallenbach (Geneva): vdallenbach@dndi.org +41 22 906 92 47 / +41 79 424 14 74 (mobile)
About Drugs for Neglected Diseases initiative (DNDi)
DNDi is a not-for-profit research and development (R&D) organization working to deliver new treatments for the most neglected diseases, in particular sleeping sickness (human African trypanosomiasis), Chagas disease, leishmaniasis, filarial (parasitic worm infections), and paediatric HIV.
Since its inception in 2003, DNDi has delivered six treatments: two fixed-dose antimalarials (ASAQ and ASMQ), nifurtimox-eflornithine combination therapy (NECT) for late-stage sleeping sickness, sodium stibogluconate and paromomycin (SSG&PM) combination therapy for visceral leishmaniasis in Africa, a set of combination therapies for visceral leishmaniasis in Asia, and a paediatric dosage form of benznidazole for Chagas disease in Latin America.
DNDi was established in 2003 by MSF, the Indian Council of Medical Research, Brazil's Oswaldo Cruz Foundation, the Kenya Medical Research Institute, the Ministry of Health of Malaysia, and the Institut Pasteur in France, with the Special Programme for Research and Training in Tropical Diseases (WHO-TDR) as a permanent observer.
www.dndi.org
About 'Connect to Fight Neglect'
As part of its 10th anniversary, DNDi has launched a special advocacy website to give voice and attention to neglected patients and those working to develop and deliver life-saving treatments for them. The 'Connect to Fight Neglect' website is a multimedia web portal where videos, photos, audio, testimonials, stories, and opinions can be shared about some of the world's most neglected diseases, the people whose lives are diminished and threatened by these conditions, and the research and care efforts under way around the world. Among the people featured are patients, doctors, researchers, public health officials, policymakers, funders, and activists.
[1] Mapping of available health research and development data: What's there, what's missing, and what role is there for a global observatory? Rottingen J-A et al. The Lancet, Online Publication, 20 May 2013 - doi:10.1016/S0140-6736(13)61046-6
[2] Medical innovations for neglected patients, DNDi-MSF, December 2012.